Literature DB >> 35241567

Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.

Kazuhiko Yoshida1, Keisuke Hata2, Junpei Iizuka2, Tsunenori Kondo3, Hiroki Ishihara3, Hideki Ishida2, Yoji Nagashima4, Kazunari Tanabe2, Toshio Takagi2.   

Abstract

BACKGROUND/AIM: The efficacy of immune checkpoint inhibitor (ICI) combinations in treating inferior vena cava (IVC) tumour thrombi has not yet been reported. We aimed to evaluate the clinical efficacy of ICIs for patients with renal cell carcinoma (RCC) and a concomitant IVC tumour thrombus. PATIENTS AND METHODS: Three men and two women with RCC and an IVC tumour thrombus were administered ICIs in 2020-2021. Three and two patients received nivolumab plus ipilimumab and pembrolizumab plus axitinib therapy, respectively.
RESULTS: All ICI-treated patients showed tumour shrinkage. The IVC thrombus level was downstaged in two patients. The mean reduction in maximum primary tumour diameter and IVC thrombus height was 34 and 33 mm, respectively.
CONCLUSION: Presurgical ICI therapy in three patients who underwent radical nephrectomy with thrombectomy resulted in a modified surgical strategy and approach and reduced surgical risk. Thus, ICIs may treat select cases of RCC with an IVC tumour thrombus effectively.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Immune checkpoint inhibitor; inferior vena cava; renal cell carcinoma; thrombus

Mesh:

Substances:

Year:  2022        PMID: 35241567      PMCID: PMC8931899          DOI: 10.21873/invivo.12798

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  16 in total

1.  Surgical Resection of Malignancies Invading Inferior Vena Cava Level I and II. Issues Still Need to Be Discussed.

Authors:  Emilio Vicente; Yolanda Quijano; Benedetto Ielpo; Hipolito Duran; Eduardo Diaz; Isabel Fabra; Luis Malavé; Valentina Ferri; Antonio Ferronetti; Riccardo Caruso
Journal:  Anticancer Res       Date:  2017-05       Impact factor: 2.480

2.  Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.

Authors:  Hironori Fukuda; Tsunenori Kondo; Toshio Takagi; Jumpei Iizuka; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2017-04-01       Impact factor: 3.402

3.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

4.  Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?

Authors:  Pierre Bigot; Tarek Fardoun; Jean Christophe Bernhard; Evanguelos Xylinas; Julien Berger; Morgan Rouprêt; Jean-Baptiste Beauval; Samuel Lagabrielle; Souhil Lebdai; Myriam Ammi; Hervé Baumert; Bernard Escudier; Nicolas Grenier; Jean-François Hétet; Jean-Alexandre Long; Philippe Paparel; Nathalie Rioux-Leclercq; Michel Soulié; Abdel-Rahmène Azzouzi; Karim Bensalah; Jean-Jacques Patard
Journal:  World J Urol       Date:  2013-04-27       Impact factor: 4.226

5.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

6.  Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus.

Authors:  Erica H Lambert; Phillip M Pierorazio; Ahmad Shabsigh; Carl A Olsson; Mitchell C Benson; James M McKiernan
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

7.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

8.  Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis.

Authors:  Yasuyoshi Okamura; Tomoaki Terakawa; Mariko Sakamoto; Yukari Bando; Kotaro Suzuki; Takuto Hara; Junya Furukawa; Kenichi Harada; Nobuyuki Hinata; Yuzo Nakano; Masato Fujisawa
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

9.  Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.

Authors:  Jens Bedke; Laurence Albiges; Umberto Capitanio; Rachel H Giles; Milan Hora; Thomas B Lam; Börje Ljungberg; Lorenzo Marconi; Tobias Klatte; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Thomas Powles; Axel Bex
Journal:  Eur Urol       Date:  2020-12-24       Impact factor: 20.096

10.  Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution.

Authors:  Takeshi Ujike; Motohide Uemura; Atsunari Kawashima; Akira Nagahara; Kazutoshi Fujita; Yasushi Miyagawa; Norio Nonomura
Journal:  Anticancer Drugs       Date:  2016-11       Impact factor: 2.248

View more
  2 in total

1.  Presurgical avelumab plus axitinib in an immunosenescent octogenarian with renal cell carcinoma invading the vena cava.

Authors:  Toshitaka Uematsu; Toshiki Kijima; Atsuko Takada-Owada; Daisaku Nishihara; Kazuyuki Ishida; Takao Kamai
Journal:  Urol Case Rep       Date:  2022-08-31

2.  Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Renal Cell Carcinoma and Venous Tumor Thrombus: A Population-Based Study.

Authors:  Lin Yang; Bin Fu
Journal:  Front Surg       Date:  2022-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.